Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Share-based Compensation (2016 - 2025)

Tvardi Therapeutics' Share-based Compensation history spans 13 years, with the latest figure at $353000.0 for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 346.84% to $353000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.7 million, a 23.39% decrease, with the full-year FY2025 number at $1.4 million, up 338.56% from a year prior.
  • Share-based Compensation hit $353000.0 in Q4 2025 for Tvardi Therapeutics, up from $339000.0 in the prior quarter.
  • Over the last five years, Share-based Compensation for TVRD hit a ceiling of $8.8 million in Q4 2021 and a floor of $79000.0 in Q2 2024.
  • Historically, Share-based Compensation has averaged $2.1 million across 5 years, with a median of $1.4 million in 2023.
  • Biggest five-year swings in Share-based Compensation: surged 1239.81% in 2023 and later plummeted 97.81% in 2024.
  • Tracing TVRD's Share-based Compensation over 5 years: stood at $8.8 million in 2021, then tumbled by 56.73% to $3.8 million in 2022, then dropped by 5.26% to $3.6 million in 2023, then plummeted by 97.81% to $79000.0 in 2024, then skyrocketed by 346.84% to $353000.0 in 2025.
  • Business Quant data shows Share-based Compensation for TVRD at $353000.0 in Q4 2025, $339000.0 in Q3 2025, and $627000.0 in Q2 2025.